Boston Scientific (NYSE: BSX) today shared study data supporting the use of its Eluvia drug-eluting stent for treating PAD.

Surmodics, Inc. announced the publication of results from the TRANSCEND clinical trial. The global randomized study demonstrat ...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the publication of the TRANSCEND clinical trial, ...

Surmodics (SRDX) announced the publication of the TRANSCEND clinical trial, a global randomized study demonstrating the SurVeil drug-coated ...

Endologix has reported the 36-month outcomes of a study that evaluated its DETOUR System for treating complex peripheral arterial disease ... for fully percutaneous femoropopliteal bypass procedures.

Ulf Teichgräber “Historically, paclitaxel-coated balloon angioplasty has been the mainstay therapy for PAD, particularly in the femoropopliteal vascular segment, and is based on the “leaving ...

A total of 446 patients with femoropopliteal artery disease (Rutherford stages 2–4) were randomized to either the SurVeil DCB (n = 222) or the IN.PACT Admiral DCB (n = 224). Patients were ...